Table 1.
Estimated undetected cancers during the COVID-19 pandemic in Catalonia. Comparison of cancer incidence in the Catalan Pathology Registry (CPR) between pre-pandemic (2019) and pandemic (March 2020-January 2022) periods by age and tumor site (both sexes)
| 0-49 |
50-69 |
>=70 |
All ages |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tumor site | O | E | Dif | SIR (95% CI) | O | E | Dif | SIR (95% CI) | O | E | Dif | SIR (95% CI) | O | E | Dif | SIR (95% CI) |
| Lip, oral cavity, pharynx (COO-C14) | 182 | 223 | −41 | 0.82 (0.70-0.94) | 843 | 1069 | −226 | 0.79 (0.74-0.84) | 868 | 1032 | −164 | 0.84 (0.79-0.90) | 1893 | 2324 | −431 | 0.81 (0.78-0.85) |
| Esophagus (C15) | 58 | 41 | 17 | 1.42 (1.08-1.83) | 330 | 356 | −26 | 0.93 (0.83-1.03) | 294 | 341 | −47 | 0.86 (0.77-0.97) | 682 | 738 | −56 | 0.92 (0.86-1.00) |
| Stomach (C16) | 110 | 159 | −49 | 0.69 (0.57-0.84) | 583 | 720 | −137 | 0.81 (0.75-0.88) | 859 | 1101 | −242 | 0.78 (0.73-0.83) | 1552 | 1980 | −428 | 0.78 (0.75-0.82) |
| Colon, rectum, anus (C17-C21) | 427 | 504 | −77 | 0.85 (0.77-0.93) | 2993 | 3710 | −717 | 0.81 (0.78-0.84) | 4299 | 4827 | −528 | 0.89 (0.86-0.92) | 7719 | 9041 | −1322 | 0.85 (0.83-0.87) |
| Liver, gallbladder, ext. bile ducts (C22-C24) | 246 | 251 | −5 | 0.98 (0.86-1.11) | 1393 | 1447 | −54 | 0.96 (0.91-1.01) | 1356 | 1551 | −195 | 0.87 (0.83-0.92) | 2995 | 3249 | −254 | 0.92 (0.89-0.96) |
| Pancreas (C25) | 65 | 59 | 6 | 1.10 (0.85-1.40) | 412 | 398 | 14 | 1.03 (0.94-1.14) | 449 | 452 | −3 | 0.99 (0.90-1.09) | 926 | 910 | 16 | 1.02 (0.95-1.09) |
| Larynx (C32) | 24 | 49 | −25 | 0.49 (0.31-0.73) | 420 | 486 | −66 | 0.86 (0.78-0.95) | 273 | 340 | −67 | 0.80 (0.71-0.90) | 717 | 875 | −158 | 0.82 (0.76-0.88) |
| Lung (C34) | 264 | 317 | −53 | 0.83 (0.74-0.94) | 2627 | 2975 | −348 | 0.88 (0.85-0.92) | 2470 | 2789 | −319 | 0.89 (0.85-0.92) | 5361 | 6080 | −719 | 0.88 (0.86-0.91) |
| Thymus, heart, mediast., pleura (C37-C39) | 12 | 20 | −8 | 0.59 (0.30-1.03) | 48 | 46 | 2 | 1.04 (0.76-1.37) | 80 | 115 | −35 | 0.69 (0.55-0.86) | 140 | 182 | −42 | 0.77 (0.65-0.91) |
| Bones (C40-C41) | 37 | 62 | −25 | 0.60 (0.42-0.83) | 33 | 41 | −8 | 0.80 (0.55-1.13) | 23 | 10 | 13 | 2.37 (1.50-3.56) | 93 | 113 | −20 | 0.83 (0.67-1.01) |
| Soft tissues (C47-C49) | 166 | 163 | 3 | 1.02 (0.87-1.19) | 251 | 308 | −57 | 0.81 (0.72-0.92) | 177 | 218 | −41 | 0.81 (0.70-0.94) | 594 | 690 | −96 | 0.86 (0.79-0.93) |
| Skin, melanoma (C44) | 315 | 344 | −29 | 0.91 (0.82-1.02) | 493 | 566 | −73 | 0.87 (0.80-0.95) | 562 | 653 | −91 | 0.86 (0.79-0.93) | 1370 | 1564 | −194 | 0.88 (0.83-0.92) |
| Skin, nonmelanoma (C44) | 1677 | 1857 | −180 | 0.90 (0.86-0.95) | 5749 | 7124 | −1375 | 0.81 (0.79-0.83) | 14 058 | 17 917 | −3859 | 0.78 (0.77-0.80) | 21 484 | 26 898 | −5414 | 0.80 (0.79-0.81) |
| Breast (C50) | 1808 | 1993 | −185 | 0.91 (0.87-0.95) | 3869 | 4278 | −409 | 0.90 (0.88-0.93) | 2676 | 2841 | −165 | 0.94 (0.91-0.98) | 8353 | 9112 | −759 | 0.92 (0.90-0.94) |
| Vulva, vagina (C51-C52) | 45 | 31 | 14 | 1.46 (1.07-1.96) | 102 | 146 | −44 | 0.70 (0.57-0.85) | 239 | 251 | −12 | 0.95 (0.84-1.08) | 386 | 427 | −41 | 0.90 (0.82-1.00) |
| Cervix (C53) | 208 | 247 | −39 | 0.84 (0.73-0.97) | 187 | 243 | −56 | 0.77 (0.66-0.89) | 151 | 127 | 24 | 1.19 (1.00-1.39) | 546 | 617 | −71 | 0.89 (0.81-0.96) |
| Endometrium (C54) | 182 | 163 | 19 | 1.12 (0.96-1.29) | 807 | 874 | −67 | 0.92 (0.86-0.99) | 632 | 605 | 27 | 1.04 (0.96-1.13) | 1621 | 1642 | −21 | 0.99 (0.94-1.04) |
| Ovary (C56) | 153 | 162 | −9 | 0.95 (0.80-1.11) | 306 | 259 | 47 | 1.18 (1.05-1.32) | 150 | 137 | 13 | 1.10 (0.93-1.29) | 609 | 558 | 51 | 1.09 (1.01-1.18) |
| Prostate (C61.9) | 53 | 61 | −8 | 0.87 (0.65-1.14) | 2533 | 2908 | −375 | 0.87 (0.84-0.91) | 3280 | 3849 | −569 | 0.85 (0.82-0.88) | 5866 | 6818 | −952 | 0.86 (0.84-0.88) |
| Testis (C62) | 208 | 259 | −51 | 0.80 (0.70-0.92) | 45 | 52 | −7 | 0.87 (0.64-1.17) | 19 | 12 | 7 | 1.64 (0.99-2.57) | 272 | 322 | −50 | 0.85 (0.75-0.95) |
| Kidney (C64) | 182 | 178 | 4 | 1.02 (0.88-1.18) | 711 | 820 | −109 | 0.87 (0.80-0.93) | 612 | 661 | −49 | 0.93 (0.85-1.00) | 1505 | 1658 | −153 | 0.91 (0.86-0.95) |
| Urinary tract (C66.9-C68) | 98 | 132 | −34 | 0.75 (0.60-0.91) | 1528 | 1588 | −60 | 0.96 (0.91-1.01) | 2642 | 2768 | −126 | 0.95 (0.92-0.99) | 4268 | 4488 | −220 | 0.95 (0.92-0.98) |
| Meninges, brain, spinal cord (C70-C72) | 290 | 435 | −145 | 0.67 (0.59-0.75) | 526 | 610 | −84 | 0.86 (0.79-0.94) | 253 | 354 | −101 | 0.71 (0.63-0.81) | 1069 | 1399 | −330 | 0.76 (0.72-0.81) |
| Thyroid (C73.9) | 350 | 443 | −93 | 0.79 (0.71-0.88) | 392 | 496 | −104 | 0.79 (0.71-0.87) | 174 | 226 | −52 | 0.77 (0.66-0.89) | 916 | 1165 | −249 | 0.79 (0.74-0.84) |
| Lymphoid | 419 | 537 | −118 | 0.78 (0.71-0.86) | 834 | 1069 | −235 | 0.78 (0.73-0.84) | 1004 | 1149 | −145 | 0.87 (0.82-0.93) | 2257 | 2755 | −498 | 0.82 (0.79-0.85) |
| Myeloid | 116 | 155 | −39 | 0.75 (0.62-0.90) | 289 | 360 | −71 | 0.80 (0.71-0.90) | 430 | 540 | −110 | 0.80 (0.72-0.88) | 835 | 1055 | −220 | 0.79 (0.74-0.85) |
| Other tumor sitesa | 121 | 143 | −22 | 0.84 (0.70-1.01) | 332 | 378 | −46 | 0.88 (0.79-0.98) | 372 | 445 | −73 | 0.84 (0.75-0.93) | 825 | 966 | −141 | 0.85 (0.80-0.91) |
| Unknown primary siteb | 491 | 529 | −38 | 0.93 (0.85-1.01) | 1614 | 1709 | −95 | 0.94 (0.90-0.99) | 1632 | 1838 | −206 | 0.89 (0.85-0.93) | 3737 | 4076 | −339 | 0.92 (0.89-0.95) |
| All sites | 8307 | 9516 | −1209 | 0.87 (0.85-0.89) | 30 250 | 35 036 | −4786 | 0.86 (0.85-0.87) | 40 034 | 47 149 | −7115 | 0.85 (0.84-0.86) | 78 591 | 91 700 | −13 109 | 0.86 (0.85-0.86) |
| All but nonmelanoma of skin | 6630 | 7659 | −1029 | 0.87 (0.84-0.89) | 24 501 | 27 911 | −3410 | 0.88 (0.87-0.89) | 25 976 | 29 232 | −3256 | 0.89 (0.88-0.90) | 57 107 | 64 802 | −7695 | 0.88 (0.87-0.89) |
O: observed incident cancers in the CPR, E: expected incident cancers in the CPR, Dif: estimated number of undetected cancers, difference between O and E. The sum of the estimated undetected cancers from all tumor sites may not be equal to the total in the table. SIR (95% CI): standardized incidence ratio (95% confidence interval). 95% CIs including 1 are not statistically significant (colorless), SIRs >1 indicate significant overdiagnosis (yellow) and <1, significant underdiagnosis (red).
a
Other tumor sites include small intestine, placenta, penis, eye and adnexa, endocrine glands without thyroid.
b
Unknown primary site includes all unspecific tumour sites in specimens from the CPR.